Thymalin

Thymalin is a complex polypeptide extract isolated from calf thymus tissue, developed by Vladimir Khavinson's research group in Russia. It contains multiple short peptides and is one of the foundational compounds in the Khavinson bioregulator program. It has been registered as a medication in Russia for decades, with extensive clinical research in immune dysfunction and longevity contexts. Outside Russia it is sold for laboratory research.

Thymalin is the original 'thymus extract' bioregulator — a complex mix of small peptides extracted from calf thymus that has been used clinically in Russia for over 40 years. Unlike Thymosin Alpha-1 (a single defined peptide), Thymalin is a full extract, which researchers argue gives it a broader physiologic effect. It is a staple in Russian immune-support and longevity protocols.

Thymalin's mixed peptide composition acts on multiple targets in the immune system — supporting T-cell maturation, B-cell function, and balanced Th1/Th2 responses. The Khavinson group has published large multi-decade cohort data suggesting reductions in age-related mortality and infection rates in Thymalin-treated elderly populations.

• •Immune dysfunction in aging
• •Chronic infection support
• •Cancer adjunct therapy (Russian clinical use)
• •Khavinson 12+ year longevity cohort studies
• •Comparative thymic peptide research

Thymalin sits at the intersection of the Khavinson bioregulator community and the broader immune-peptide audience. It is often compared with Thymosin Alpha-1, with users debating extract vs single-peptide approaches.

“The OG Russian thymus extract.”

Frequently combined with Epitalon in longevity protocols and with other Khavinson bioregulators in 'full system' stacks.

Thymalin is a calf-thymus-derived polypeptide extract from the Khavinson bioregulator program, used clinically in Russia for immune dysfunction and longevity. Sold for laboratory research outside Russia.